Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCULATE-US: ctDNA-Guided Adjuvant Chemotherapy in Colon Cancer
NCT05174169Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Jul 2022
- Primary completion
- Mar 2029
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid, capecitabine and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colon cancer (4 cohorts), sponsored by NRG Oncology. Primary endpoints: Time to ctDNA positive status up to 3 years and Disease-Free Survival up to 5 years. Started Jul 2022; status: recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acidcapecitabineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05174169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174169.